Condition: Advanced or Metastatic Solid Tumor · Pancreatic Ductal Adenocarcinoma · Colorectal Cancer · Sponsor: Taiho Pharmaceutical Co., Ltd.
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
This description comes directly from the study's public registry record.
Drug Information Center · +81-3-3294-4527 · toiawase@taiho.co.jp
Always discuss trial participation with your own doctor first.
| A site selected by Taiho Pharmaceutical Co., Ltd. | Aichi, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Chiba, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Ehime, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Hokkaido, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Kanagawa, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Osaka, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Shizuoka, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Tokyo, Japan | Recruiting |
| A site selected by Taiho Pharmaceutical Co., Ltd. | Wakayama, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04999761